Matrix Metalloproteinase Inhibitors

Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES.

Also Known As:

Collagenase Inhibitors; Gelatinase Inhibitors; MMP Inhibitors; Stromelysin Inhibitors; Inhibitor, Collagenase; Inhibitor, Gelatinase; Inhibitor, MMP; Inhibitor, Matrix Metalloproteinase; Inhibitors, Collagenase; Inhibitors, Gelatinase; Inhibitors, MMP; Inhibitors, Matrix Metalloproteinase; Inhibitors, Stromelysin; Metalloproteinase Inhibitor, Matrix; Metalloproteinase Inhibitors, Matrix; Collagenase Inhibitor; Gelatinase Inhibitor; MMP Inhibitor; Matrix Metalloproteinase Inhibitor

Networked: 1216 relevant articles (73 outcomes, 277 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Protease Inhibitors: 6291
        Matrix Metalloproteinase Inhibitors: 1216

Experts

1.	Schulz, Richard: 12 articles (01/2021 - 09/2003)
2.	Opdenakker, Ghislain: 10 articles (07/2019 - 06/2003)
3.	Chang, Mayland: 10 articles (05/2019 - 05/2005)
4.	Sorsa, Timo: 10 articles (02/2012 - 01/2006)
5.	Mobashery, Shahriar: 9 articles (05/2018 - 05/2005)
6.	Tanus-Santos, Jose E: 9 articles (01/2014 - 06/2010)
7.	Matrisian, Lynn M: 9 articles (12/2008 - 03/2002)
8.	Krell, Hans-Willi: 8 articles (02/2007 - 03/2002)
9.	Werb, Zena: 7 articles (05/2015 - 03/2003)
10.	Van den Steen, Philippe E: 7 articles (03/2014 - 06/2003)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2003 - "The authors' preclinical data suggest that the combination of inexpensive, nontoxic, oral COX-2 and MMP inhibitors may be useful for the treatment of some types of solid tumors." 05/15/2001 - "Moreover, it may be helpful in the interpretation of recent data on the use of specific MMP inhibitors in the treatment of several types of cancer." 12/27/2000 - "Based on this evidence, the pharmaceutical industry produced several well tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer models. " 01/01/2020 - "Although several MMP inhibitors (MMPi) have been developed to date for the treatment of cancer, they have all failed in clinical trials due to lack of efficacy and, most importantly, the presence of severe side effects. " 01/01/2013 - "MMP inhibitors and cancer treatment trials, limitations and hopes for the future."
2.	Neoplasm Metastasis (Metastasis) 05/01/2003 - "Similarly the treatment of mice bearing bone metastasis with an MMP inhibitor led to a significant reduction of serum ICTP and CTX, and osteolytic lesions. " 03/01/2013 - "Although MMP inhibitors showed early promise in preventing metastasis in animal models, they have largely failed clinically. " 10/01/2016 - "We hypothesized that early treatment with a selective MMP inhibitor between the time of diagnosis and definitive surgery, the so-called "window-of-opportunity," can inhibit metastasis and thereby improve survival. " 01/01/2008 - "However, there are few reports describing which steps in the metastasis process are most critical for inhibition by MMP inhibitors. " 06/01/2006 - "The use of the highly selective gelatinase inhibitors holds the promise of effective intervention of metastases of PC to the bone."
3.	Inflammation (Inflammations) 01/01/2008 - "In contrast, mice treated with a broad gelatinase inhibitor showed rather inferior protection against I/R injury and were characterized by persistent ongoing liver inflammation, suggesting that MMP-2 and MMP-9 may have distinct roles in this type of injury. " 01/01/2023 - "Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases." 08/01/2012 - "This rise in status has led to the development of MMP inhibitors which can act as switches or delicate tuners in acute and chronic inflammation and the regenerative phase after inflammation. " 09/01/2011 - "To modulate inflammation and tissue remodeling, the broad-spectrum MMP inhibitor SC080 was administered after the allograft was obliterated, starting at post-transplant day 21. " 06/01/2007 - "Administration of an MMP inhibitor results in a decreased rate of inflammation-mediated preterm delivery in this animal model."
4.	Stroke (Strokes) 01/01/2013 - "Recent studies implicating MMP-9 in aberrant synaptic plasticity underlying neuropsychiatric disorders, as well as in aggravating detrimental effects of the brain stroke, appear to offer a new hope for application of MMP inhibitors in treatment of those conditions." 01/12/2011 - "In the present study we examined a novel MMP-inhibitor (Ro 28-2653) with high selectivity for MMP2, MMP9 and membrane type 1-MMP in an acute stroke model comparing two different treatment regimens. " 06/01/2004 - "These studies suggest that MMP inhibitors have therapeutic potential for use in stroke, and support the increasing evidence that microglial activation may contribute to neuronal cell death." 11/26/2015 - "Additionally, treatment with MMP-inhibitor once but not twice following stroke rescued plasticity, normally lost under these conditions. " 09/01/2005 - "Novel MMP inhibitor has potential for treatment of stroke."
5.	Reperfusion Injury 06/01/2009 - "The purpose of this study was to evaluate the ability of novel semiselective matrix metalloproteinase inhibitors (MMPI) to protect myocardial structure-function in the setting of ischemia-reperfusion injury. " 05/01/2006 - "Little is known about the effects of MMP inhibitors on hepatic ischemia/reperfusion injury. " 02/01/2006 - "Matrix metalloproteinase inhibitor (ONO-4817) attenuates ischemia-reperfusion injury in rat lung." 01/01/2006 - "The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver." 01/01/2006 - "Several experimental models of liver ischemia-reperfusion injury have demonstrated protective effects of MMP inhibitors in terms of cell necrosis, apoptosis and rearrangement of the extracellular matrix. "

Related Drugs and Biologics

1.	Matrix Metalloproteinases (MMPs)
2.	Doxycycline (Periostat)
3.	Collagen
4.	N- (2(R)- 2- (hydroxamidocarbonylmethyl)- 4- methylpentanoyl)- L- tryptophan methylamide
5.	N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl- 2,5- dioxo- 1- imidazolidinyl)butyl)- L- leucyl- N,3- dimethyl-L-Valinamide
6.	prinomastat (Ag3340)
7.	Cytokines
8.	Tetracyclines
9.	SB 3CT compound
10.	Ro 28-2653

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Surgical Amputation (Amputations)
5.	Immunotherapy